New Agents and Therapeutic Strategies in β-Thalassemia

Friday Satellite Symposium on New Agents and Therapeutic Strategies in β-Thalassemia, preceding the 62nd ASH Annual Meeting and Exposition.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.


  • Welcome and Introduction
  • Optimizing Current Management of β-Thalassemia
  • Evolving Role of Biologic Therapies for β-Thalassemia
  • The Promise of Gene Therapy in β-Thalassemia
  • Final Thoughts and Audience Question and Answer Session


Date / Time
Event Details


Program Director
Janet L. Kwiatkowski, MD, MSCE

Professor of Pediatrics
Director of Thalassemia Program

Division of Hematology
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania

Jeanne Boudreaux, MD

Associate Professor of Pediatrics
Director of the Comprehensive Thalassemia Program
Clinical Director of Hematology

Aflac Cancer & Blood Disorders Center
Children's Healthcare of Atlanta
Emory University
Atlanta, Georgia

Sujit Sheth, MD

Department of Pediatrics
Weill Cornell Medicine
New York, New York

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners in using novel curative and noncurative therapeutic options for patients with β-thalassemia.

Target Audience
This program is intended for hematologists and other clinicians involved in the management of patients with β-thalassemia.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate the medical need for novel therapeutic strategies for the management of β-thalassemia
  • Describe the safety and efficacy evidence for novel approaches to reducing transfusion dependence through the use of erythroid maturation agents
  • Explain the mechanism of action of gene therapy as a curative approach to β-thalassemia
  • Examine key efficacy and safety data on emerging gene therapy strategies and their potential role in the management of patients with β-thalassemia
  • Identify patients with β-thalassemia who are candidates for ongoing clinical trials


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.